Press Release_Press Release_InxMed-Leading Innovations Targeting Tumor Defense

04

2024-06

2024-06-04

InxMed Reports Positive Phase Ib/II Results for Ifebemtinib in Combination with Garsorasib in Non-Small Cell Lung Cancer (NSCLC) with KRAS G12C Mutation

NANJING, China, June 3, 2024 -- InxMed Co., Ltd, a clinical-stage biotechnology company developing innovative therapies against tumor-treatment resistance and metastasis, today announced results from the Phase Ib/II clinical trial of ifebemtinib, the company's focal adhesion kinase (FAK) inhibitor, in combination with garsorasib, a specific inhibitor of the KRAS G12C mutation, for the first-line treatment of non-small cell lung cancer (NSCLC) with KRAS G12C mutation.

20

2023-12

2023-12-20

InxMed Enters License Agreement with Escugen to Develop Next-Generation ADCs

Nanjing, China, Dec 20, 2023 -- InxMed, a clinical-stage biotechnology company dedicates on developing innovative therapies against drug resistance, and Escugen, a clinical-stage antibody–drug conjugate (ADC) company, today announced that InxMed licensed EZWi-Fit® linker-payload platform from Escugen for the development of the next generation tumor-associated antigens (TAAs) targeting ADCs.

25

2023-10

2023-10-25

InxMed Releases Data Demonstrating Ifebemtinib (IN10018) Trending Toward Survival Benefit at ESMO 2023

NANJING, China, Oct 23, 2023 -- InxMed Co., Ltd, a clinical-stage biotechnology company dedicated on developing innovative therapies to overcome drug resistance for hard-to-treat solid tumors, announces that clinical data of Ifebemtinib (IN10018), a highly potent and selective oral inhibitor of focal adhesion kinase (FAK), in platinum-resistant recurrent ovarian cancer （PROC）and triple-negative breast cancer（TNBC）has been presented at the 2023 European Society for Medical Oncology (ESMO) Congress taking place October 20-24 in Madrid，Spain.

19

2023-10

2023-10-19

InxMed Presents New Data at 14th Annual World ADC Highlighting Synergy of IN10018 with ADCs and Novel Stroma targeting pipeline

NANJING, China, Oct 19, 2023 -- InxMed Co., Ltd, a clinical-stage biotechnology company dedicated on developing innovative therapies to overcome treatment resistance for hard-to-treat solid tumors, is presenting preclinical data at 14th Annual World ADC Conference in San Diego regarding IN10018, a highly potent and selective oral inhibitor of focal adhesion kinase (FAK), to boost efficacy of ADCs, and IN30718，a First-in-Class cancer associated fibroblast (CAF) targeting ADC for high stroma tumors.

30

2023-08

2023-08-30

InxMed Receives Approval to Initiate Phase I Clinical Trial in China for OMTX705, a First-in-Class FAP-Targeting ADC

Nanjing, China, Aug 30, 2023 InxMed, a clinical-stage biotechnology company dedicates on developing innovative therapies targeting drug resistance for hard-to-treat solid tumors，announced today the first-in-class ADC OMTX705 has obtained the IND (Investigational New Drug) approval from China National Medical Products Administration (NMPA) recently.

18

2022-10

2022-10-18

InxMed Releases Data Demonstrating IN10018 Therapeutic Potential in Patients with Metastatic Melanoma at SMR 2022

NANJING, China, Oct 18, 2022 -- InxMed Co., Ltd, a clinical-stage biotechnology company dedicates on developing innovative therapies targeting drug resistance for hard-to-treat solid tumors, is pleased to announce that the clinical data from an open-label, phase Ib trial evaluating the efficacy and safety of IN10018, a highly potent and selective oral inhibitor of focal adhesion kinase (FAK), alone or in combination with cobimetinib (Cobi, an approved mitogen-activated protein kinase [MEK] inhibitor from Roche) in patients with Uveal Melanoma (UM) and NRAS-mutant melanoma. The clinical data is being presented in the form of poster at the Society for Melanoma Research (SMR) 19th International Congress from October 17-20, 2022 (Abstract #: P-141). The released data showed that IN10018 in combination with Cobi demonstrated promising antitumor activities and acceptable safety profile in patients with metastatic melanoma. InxMed has entered into a global clinical collaboration with Roche to evaluate IN10018 in combination with Cobi before.

InxMed Reports Positive Phase Ib/II Results for Ifebemtinib in Combination with Garsorasib in Non-Small Cell Lung Cancer (NSCLC) with KRAS G12C Mutation

InxMed Enters License Agreement with Escugen to Develop Next-Generation ADCs

InxMed Releases Data Demonstrating Ifebemtinib (IN10018) Trending Toward Survival Benefit at ESMO 2023

InxMed Presents New Data at 14th Annual World ADC Highlighting Synergy of IN10018 with ADCs and Novel Stroma targeting pipeline

InxMed Receives Approval to Initiate Phase I Clinical Trial in China for OMTX705, a First-in-Class FAP-Targeting ADC

InxMed Releases Data Demonstrating IN10018 Therapeutic Potential in Patients with Metastatic Melanoma at SMR 2022

QUICK LINKS

CONTACT US

MESSAGE